Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Repligen Corp Stock Research

RGEN

162.88USD-5.70(-3.38%)Delayedas of 21 Sep 2023, 11:40 am
Watchlist

Market Summary

USD162.88-5.70
Delayedas of 21 Sep 2023, 11:40 am
-3.38%

RGEN Alerts

  • 1 major insider sales recently.
  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)

RGEN Stock Price

RGEN RSI Chart

RGEN Valuation

Market Cap

9.4B

Price/Earnings (Trailing)

68.08

Price/Sales (Trailing)

70.03

EV/EBITDA

39.77

Price/Free Cashflow

94.1

RGEN Price/Sales (Trailing)

RGEN Profitability

EBT Margin

107.47%

Return on Equity

8.65%

Return on Assets

6.61%

Free Cashflow Yield

1.06%

RGEN Fundamentals

RGEN Revenue

Revenue (TTM)

134.2M

Revenue Y/Y

-23.34%

Revenue Q/Q

-12.86%

RGEN Earnings

Earnings (TTM)

138.0M

Earnings Y/Y

-59.76%

Earnings Q/Q

-30.4%

Price Action

52 Week Range

134.64225.62
(Low)(High)

Last 7 days

6.1%

Last 30 days

4.7%

Last 90 days

12.5%

Trailing 12 Months

-21.5%

RGEN Financial Health

Current Ratio

2.51

RGEN Investor Care

Shares Dilution (1Y)

0.50%

Diluted EPS (TTM)

2.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for RGEN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-29
DAWES KAREN A
acquired
133,943
18.12
7,392
-
2023-08-29
DAWES KAREN A
sold
-145,673
171
-850
-
2023-05-18
BARTHELEMY NICOLAS
acquired
-
-
686
-
2023-05-18
DAWES KAREN A
acquired
-
-
798
-
2023-05-18
Mhatre Rohin
acquired
-
-
686
-
2023-05-18
Konstantinov Konstantin
acquired
-
-
686
-
2023-05-18
Madaus Martin D
acquired
-
-
686
-
2023-05-18
EGLINTON MANNER CARRIE
acquired
-
-
686
-
2023-05-18
MUIR GLENN P
acquired
-
-
686
-
2023-05-16
Snodgres Jon
sold (taxes)
-109,361
154
-710
chief financial officer

1–10 of 50

Which funds bought or sold RGEN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-12
Farther Finance Advisors, LLC
added
300
398
566
-%
2023-08-25
Yarbrough Capital, LLC
unchanged
-
-65,851
346,294
0.02%
2023-08-24
Alberta Investment Management Corp
unchanged
-
-1,730,560
9,100,550
0.09%
2023-08-22
COMERICA BANK
new
-
6,000
6,000
-%
2023-08-22
COMERICA BANK
new
-
17,980,000
17,980,000
1.88%
2023-08-21
OSAIC HOLDINGS, INC.
added
12.28
-114,821
1,930,070
-%
2023-08-21
BOKF, NA
reduced
-32.67
-18,351
23,907
-%
2023-08-21
OSAIC HOLDINGS, INC.
unchanged
-
-222
1,311
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
10.25
-102,000
1,291,000
0.01%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-3.14
-2,774,980
12,128,900
0.02%

1–10 of 44

Latest Funds Activity

Are funds buying RGEN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RGEN
No. of Funds

Schedule 13G FIlings of Repligen

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 15, 2023
eddleman roy t
4.87%
2,705,689
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
9.1%
5,070,657
SC 13G/A
Feb 09, 2023
vanguard group inc
9.37%
5,205,155
SC 13G/A
Jan 23, 2023
blackrock inc.
11.0%
6,123,594
SC 13G/A
Sep 08, 2022
blackrock inc.
10.2%
5,686,997
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
5.5%
3,042,655
SC 13G
Feb 10, 2022
vanguard group inc
8.89%
4,912,769
SC 13G/A
Feb 01, 2022
blackrock inc.
9.4%
5,189,189
SC 13G/A
Feb 10, 2021
vanguard group inc
8.12%
4,410,742
SC 13G/A
Feb 05, 2021
eddleman roy t
6.65%
3,500,000
SC 13G/A

Recent SEC filings of Repligen

View All Filings
Date Filed Form Type Document
Sep 12, 2023
8-K
Current Report
Aug 30, 2023
4
Insider Trading
Aug 29, 2023
144
Notice of Insider Sale Intent
Aug 02, 2023
8-K
Current Report
Aug 02, 2023
10-Q
Quarterly Report

RGEN Fair Value

Loading...

Peers (Alternatives to Repligen)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.0B
7.0B
-5.38% -12.23%
29.09
4.71
5.03% -14.68%
24.7B
4.0B
-3.30% -3.12%
27.83
6.25
2.30% 16.37%
21.9B
4.5B
-17.36% -28.94%
-5.22
4.9
-4.92% -21931.58%
11.2B
1.1B
-9.93% -5.35%
39.16
9.83
2.81% 4.86%
MID-CAP
9.4B
134.2M
4.73% -21.54%
68.08
70.03
-82.77% -13.43%
SMALL-CAP
2.4B
146.1M
-8.89% 61.75%
-7.4
16.16
4.72% -55.19%
960.9M
112.0M
5.18% 169.83%
-14.6
8.58
0.83% 16.42%
749.3M
189.6M
-19.57% -31.57%
-3.92
3.95
18.74% 17.75%
175.0M
114.1M
-1.44% 44.37%
-32.24
1.53
-5.49% -48.58%
118.7M
99.2M
-1.73% -74.89%
-2.09
1.2
-26.56% -199.52%
103.3M
80.9M
-10.97% -2.13%
-15.91
1.28
17.20% 77.07%
99.7M
31.5M
-1.32% 40.85%
-0.68
3.16
35.12% -38.47%
73.7M
143.9M
-41.73% -89.43%
-0.44
0.51
0.71% -18.99%
72.1M
52.7M
-20.39% -41.08%
-9.55
1.37
2.10% -1984.29%

Repligen News

MarketBeat
Perpetual Ltd Has $81.56 Million Holdings in Repligen Co ....
MarketBeat,
2 hours ago
Yahoo Finance

Returns for RGEN

Cumulative Returns on RGEN

32.5%


10-Year Cumulative Returns

26.0%


7-Year Cumulative Returns

25%


5-Year Cumulative Returns

4.9%


3-Year Cumulative Returns

Risks for RGEN

What is the probability of a big loss on RGEN?

67.7%


Probability that Repligen stock will be more than 20% underwater in next one year

34.6%


Probability that Repligen stock will be more than 30% underwater in next one year.

22.3%


Probability that Repligen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RGEN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Repligen was unfortunately bought at previous high price.

Drawdowns

Financials for Repligen

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-26.5%134183206801779734671593509433366327302286270253233210194184171
Gross Profit-----------21018817216115114012911610810291.00
Costs and Expenses-0.8%577582577588573543503445386339296269257249234215195179168162158
Operating Expenses-----------296269257249234215195179168162158
  S&GA Expenses-2.6%21221821621520919918416814913112011210710496.0085.0076.0069.0066.0064.0064.00
  R&D Expenses-1.7%43.0044.0044.0042.0041.0039.0034.0032.0027.0023.0020.0019.0020.0021.0019.0017.0016.0016.0016.0016.0014.00
EBITDA-100.0%-25227125224822020516914412398.0086.0069.0060.0056.00------
EBITDA Margin-100.0%-1.38*1.31*0.31*0.30*0.30*0.31*0.29*0.28*0.28*0.27*0.26*0.23*0.21*0.21*------
Interest Expenses0.3%1.001.001.004.006.009.0011.0010.0010.0011.0011.0012.0012.0011.009.008.007.007.007.007.007.00
Earnings Before Taxes-17.6%16219621920119517915413311082.0059.0049.0033.0026.0026.0029.0034.0027.0021.0016.007.00
EBT Margin-100.0%-1.07*1.06*0.25*0.25*0.24*0.23*0.23*0.22*0.19*0.16*0.15*0.11*0.09*0.10*------
Net Income-17.8%13816818616615914612811910080.0060.0044.0031.0023.0021.0023.0027.0021.0017.0023.0023.00
Net Income Margin-100.0%-0.92*0.90*0.21*0.20*0.20*0.19*0.20*0.20*0.18*0.16*0.13*0.10*0.08*0.08*------
Free Cashflow-100.0%-94.0087.0063.0045.0046.0052.0038.0044.0036.0040.0047.0046.0046.0049.00------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets0.4%2,5492,5382,5252,4632,4452,3842,3582,2412,0161,9271,9031,4761,4421,4061,4001,3791,068798775762745
  Current Assets-2.0%9991,019998953976945932911984926902697687651642622316284276267253
    Cash Equivalents16.8%604517523573597585604621734711717553560539537522218196194190176
  Inventory-1.6%24124523824323921418415613611095.0079.0070.0062.0055.0052.0051.0045.0042.0042.0041.00
  Net PPE5.1%20319319117416814812510085.0072.0067.0055.0052.0050.0048.0043.0038.0035.0032.0029.0024.00
  Goodwill1.7%87185685685185485986083461861861848213.00468468469470326327327327
Liabilities-3.3%578598614627640617608526413371374351342337340334189173159--
  Current Liabilities-7.8%37440540441142442437534933231331951.0044.0042.0048.0039.00141130130130121
Shareholder's Equity1.6%1,9711,9401,9111,8351,8051,7661,7501,7151,6031,5561,5291,1251,1001,0701,0601,045879625616606599
  Retained Earnings4.7%44642639734930825817.0016513195.0066.0046.0032.0016.006.002.001.00-7.51-0.68-21.21-26.00
  Additional Paid-In Capital1.1%1,5611,5451,5471,5411,5341,5291,5721,5601,4751,4681,4611,0881,0821,0741,0681,064893646643639635
Shares Outstanding0.2%56.0056.0056.0056.0055.0055.0055.0055.0055.0055.0055.0053.0052.0052.0052.0051.0046.0044.0044.0044.0044.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-7.0%14916017216014113311984.0083.0062.0063.0065.0066.0067.0067.0055.0053.0041.0033.0042.0021.00
  Share Based Compensation-5.6%25.0027.0027.0028.0029.0029.0028.0025.0022.0019.0017.0016.0015.0014.0013.0012.0012.0011.0010.0010.009.00
Cashflow From Investing42.5%-123-214-233-174-249-240-221-317-218-205-201-50.21-23.52-206-205-203-200-16.30-14.04-10.20-117
Cashflow From Financing-60.0%-17.41-10.88-13.34-12.83-14.20-11.571.003003013053067.003004864854861923.003.003.00132

RGEN Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Revenue$ 159,169$ 207,633$ 341,829$ 414,033
Costs and operating expenses:    
Cost of product revenue79,30786,260161,152168,616
Research and development9,70610,44021,86022,595
Selling, general and administrative48,96654,649105,136108,949
Contingent consideration1,791(6,884)3,026(9,295)
Total costs and operating expenses139,770144,465291,174290,865
Income from operations19,39963,16850,655123,168
Other income (expenses):    
Investment income5,96470811,450785
Interest expense(274)(271)(544)(563)
Amortization of debt issuance costs(457)(453)(914)(905)
Other expenses528(3,396)605(3,798)
Other income (expenses), net5,761(3,412)10,597(4,481)
Income before income taxes25,16059,75661,252118,687
Income tax provision5,0969,89512,35921,862
Net income$ 20,064$ 49,861$ 48,893$ 96,825
Earnings per share:    
Basic$ 0.36$ 0.9$ 0.88$ 1.75
Diluted (Note 11)$ 0.35$ 0.88$ 0.86$ 1.68
Weighted average common shares outstanding:    
Basic55,70555,44455,64855,399
Diluted (Note 11)56,85856,72156,93257,842
Net Income (Loss)$ 20,064$ 49,861$ 48,893$ 96,825
Other comprehensive income (loss):    
Foreign currency translation adjustment(6,068)(15,517)(2,795)(20,205)
Comprehensive income13,99634,34446,09876,620
Products    
Revenue:    
Revenue159,133207,597341,754413,960
Royalty and other revenue    
Revenue:    
Revenue$ 36$ 36$ 75$ 73

RGEN Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 603,656$ 523,458
Marketable securities held to maturity0100,299
Accounts receivable, net of reserves of $1,571 and $1,365 at June 30, 2023 and December 31, 2022, respectively120,304116,247
Inventories, net240,869238,277
Prepaid expenses and other current assets33,75419,837
Total current assets998,583998,118
Property, plant and equipment, net202,564190,673
Intangible assets, net351,704353,676
Goodwill870,688855,513
Deferred tax assets1,756840
Operating lease right of use assets122,044125,023
Other noncurrent assets1,664815
Total noncurrent assets1,550,4201,526,540
Total assets2,549,0032,524,658
Current liabilities:  
Accounts payable23,78727,554
Operating lease liability2,8896,957
Current contingent consideration16,36313,950
Accrued liabilities45,02371,120
Convertible Senior Notes, net285,521284,615
Total current liabilities373,583404,196
Deferred tax liabilities21,89723,000
Noncurrent operating lease liability134,438131,389
Noncurrent contingent consideration44,27751,559
Other noncurrent liabilities3,8823,814
Total noncurrent liabilities204,494209,762
Total liabilities578,077613,958
Commitments and contingencies (Note 8)
Stockholders' equity:  
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding00
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,744,896 shares at June 30, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding557556
Additional paid-in capital1,561,3931,547,266
Accumulated other comprehensive loss(37,189)(34,394)
Accumulated earnings446,165397,272
Total stockholders' equity1,970,9261,910,700
Total liabilities and stockholders' equity$ 2,549,003$ 2,524,658
Tony J. Hunt
1850
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.